Following a full submission
dasatinib 20mg, 50mg, 70mg (Sprycel®) is not recommended for use within NHS Scotland for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.
It has been associated with haematological and cytogenetic responses in patients resistant or intolerant to existing treatment. However, the economic case was not sufficiently robust and the manufacturer’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC.
Download detailed advice48KB (PDF)
- Medicine name:
- dasatinib (Sprycel)
- SMC ID:
- Philadelphia chromosome positive (PH+) actue lymphoblastic leukaemia
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Not recommended
- Date advice published:
- 07 May 2007